China NMPA Drug Inspection - Unknown - Eriocaulon

The Anhui Provincial Drug Administration released its Drug Quality Bulletin (Issue 4, 2019) on March 30, 2020, following a series of quality inspections across the province's drug supply chain. The report identifies 12 batches of 11 different drug varieties that failed to meet safety and quality standards. Several companies were cited, including Tongling Hetian Traditional Chinese Medicine Pieces Co., Ltd., Sichuan Daqian Pharmaceutical Co., Ltd., and Bozhou City Jingwan Traditional Chinese Medicine Pieces Factory. The inspections, conducted under the framework of the Chinese Pharmacopoeia (2015 Edition) and relevant provincial processing standards, revealed several significant violations. These included physical defects like insect infestation and improper processing, such as unpeeled surfaces or fibrous roots in herbal medicines, as well as chemical and safety failures including excessive moisture, high total ash content, and the presence of harmful aflatoxins. Other technical issues involved weight variations, failed microbial limit tests, and inconsistent content uniformity. In response to these findings, the regulatory authorities have initiated legal investigations into the manufacturers and distributors involved. The NMPA mandates that market supervision departments handle the non-compliant batches and take enforcement actions against the responsible parties to ensure public safety and compliance with pharmaceutical quality standards.